Abstract
Background: Use of calcium channel blockers (CCBs) has been associated with increased risk of breast cancer in some, but not all, studies. Differences in reported associations from prior studies may be due, in part, to inadequate control of confounding factors. Methods: Participants were 28, 561 postmenopausal women from the Women's Health Initiative who reported use of either CCBs or other antihypertensive medications (AHMs) at baseline; 1, 402 incident breast cancer cases were diagnosed during 12 years of follow-up. Adjusted Cox regression models were used to estimate HRs and 95% confidence intervals (CI) for the associations between CCB use relative to other AHMuse and breast cancer risk. Results: Use of CCBs was not associated with breast cancer risk (HR, 1.06; 95% CI, 0.94-1.20) relative to use of other AHMs. Associations approximated the null value when CCBs were considered by duration of use, length of action, or drug class. Conclusions: We provide additional evidence that CCBs do not influence breast cancer risk in postmenopausal women. Impact: The results from this study, which includes strong control for potential confounding factors, cast doubt on increases in risk with CCBs. Cancer Epidemiol Biomarkers Prev; 26(8); 1345-8.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1345-1348 |
| Number of pages | 4 |
| Journal | Cancer Epidemiology Biomarkers and Prevention |
| Volume | 26 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 1 2017 |
Fingerprint
ASJC Scopus subject areas
- Epidemiology
- Oncology
Cite this
Use of calcium channel blockers and breast cancer risk in the women's health initiative. / Brasky, Theodore M.; Krok-Schoen, Jessica L.; Liu, Jingmin; Chlebowski, Rowan T.; Freudenheim, Jo L.; Lavasani, Sayeh; Margolis, Karen L.; Qi, Lihong; Reding, Kerryn W.; Shields, Peter G.; Simon, Michael S.; Wactawski-Wende, Jean; Wang, Ange; Womack, Catherine; Manson, Jo Ann E.
In: Cancer Epidemiology Biomarkers and Prevention, Vol. 26, No. 8, 01.08.2017, p. 1345-1348.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Use of calcium channel blockers and breast cancer risk in the women's health initiative
AU - Brasky, Theodore M.
AU - Krok-Schoen, Jessica L.
AU - Liu, Jingmin
AU - Chlebowski, Rowan T.
AU - Freudenheim, Jo L.
AU - Lavasani, Sayeh
AU - Margolis, Karen L.
AU - Qi, Lihong
AU - Reding, Kerryn W.
AU - Shields, Peter G.
AU - Simon, Michael S.
AU - Wactawski-Wende, Jean
AU - Wang, Ange
AU - Womack, Catherine
AU - Manson, Jo Ann E.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Background: Use of calcium channel blockers (CCBs) has been associated with increased risk of breast cancer in some, but not all, studies. Differences in reported associations from prior studies may be due, in part, to inadequate control of confounding factors. Methods: Participants were 28, 561 postmenopausal women from the Women's Health Initiative who reported use of either CCBs or other antihypertensive medications (AHMs) at baseline; 1, 402 incident breast cancer cases were diagnosed during 12 years of follow-up. Adjusted Cox regression models were used to estimate HRs and 95% confidence intervals (CI) for the associations between CCB use relative to other AHMuse and breast cancer risk. Results: Use of CCBs was not associated with breast cancer risk (HR, 1.06; 95% CI, 0.94-1.20) relative to use of other AHMs. Associations approximated the null value when CCBs were considered by duration of use, length of action, or drug class. Conclusions: We provide additional evidence that CCBs do not influence breast cancer risk in postmenopausal women. Impact: The results from this study, which includes strong control for potential confounding factors, cast doubt on increases in risk with CCBs. Cancer Epidemiol Biomarkers Prev; 26(8); 1345-8.
AB - Background: Use of calcium channel blockers (CCBs) has been associated with increased risk of breast cancer in some, but not all, studies. Differences in reported associations from prior studies may be due, in part, to inadequate control of confounding factors. Methods: Participants were 28, 561 postmenopausal women from the Women's Health Initiative who reported use of either CCBs or other antihypertensive medications (AHMs) at baseline; 1, 402 incident breast cancer cases were diagnosed during 12 years of follow-up. Adjusted Cox regression models were used to estimate HRs and 95% confidence intervals (CI) for the associations between CCB use relative to other AHMuse and breast cancer risk. Results: Use of CCBs was not associated with breast cancer risk (HR, 1.06; 95% CI, 0.94-1.20) relative to use of other AHMs. Associations approximated the null value when CCBs were considered by duration of use, length of action, or drug class. Conclusions: We provide additional evidence that CCBs do not influence breast cancer risk in postmenopausal women. Impact: The results from this study, which includes strong control for potential confounding factors, cast doubt on increases in risk with CCBs. Cancer Epidemiol Biomarkers Prev; 26(8); 1345-8.
UR - http://www.scopus.com/inward/record.url?scp=85026838190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026838190&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-17-0096
DO - 10.1158/1055-9965.EPI-17-0096
M3 - Article
C2 - 28765339
AN - SCOPUS:85026838190
VL - 26
SP - 1345
EP - 1348
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
SN - 1055-9965
IS - 8
ER -